Background: Adenoid cystic carcinoma is a locally aggressive salivary gland neoplasm, which has a poor long-term prognosis. A chromosomal translocation involving the genes encoding the transcription factors, MYB and NFIB, has been recently discovered in these tumors.
A denoid cystic carcinoma is a salivary gland tumor with locally aggressive behavior and a poor prognosis. A cytogenetic abnormality has been identified in several cases involving a t(6;9) (q22-23; p23-24) translocation. 5 Recently, it has been found that the gene encoding the transcription factor MYB [v-myb myeloblastosis viral oncogene homolog (avian)] is fused with the NF (nuclear factor IB) transcription factor in 6 of 11 cases of adenoid cystic carcinoma from the salivary gland and breast. 6 The discovery of this potentially pathognomonic translocation suggests that this could be useful for diagnostic, prognostic, and potentially therapeutic purposes. To ascertain the diagnostic and prognostic use of the MYB translocation and of elevated levels of MYB expression, we examined, by fluorescence in situ hybridization (FISH) and immunohistochemistry, the status of MYB in 37 adenoid cystic carcinomas, 112 other salivary gland tumors, and 409 nonsalivary gland neoplasms.
MATERIALS AND METHOD Tissue Microarray Construction
Fifty-two cases of adenoid cystic carcinoma used to construct the tissue microarray (TMA) represented samples from patients treated in the Stanford Department of Radiation Oncology, who had specimens stored in the Surgical Pathology archives at Stanford Hospital and Clinics.
The 112 cases for the nonadenoid cystic salivary gland TMA were identified by searching the Surgical Pathology archives from January 1, 1995 to January 10, 2010, for salivary gland, palate, sublingual, and buccal specimens with a diagnosis of mucoepidermoid carcinoma (23 cases), acinic cell carcinoma (7 cases), polymorphous low-grade carcinoma (12 cases), myoepithelioma (5 cases), myoepithelial or epithelial-myoepithelial carcinoma (4 cases), pleomorphic adenoma (benign mixed tumor)/cellular pleomorphic adenoma/carcinoma expleomorphic adenoma (35 cases), oncocytic hyperplasia/ oncocytoma/oncocytic carcinoma (12 cases), basal cell adenoma/adenocarcinoma (9 cases), salivary duct carcinoma (3 cases), and adenosquamous carcinoma (5) .
The TMAs of nonsalivary gland neoplasms were constructed earlier and described elsewhere. 3 All salivary gland and nonsalivary gland cases were reviewed by a pathologist for diagnostic accuracy.
The TMAs were constructed by using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD) following the techniques described in Ref. 17 . Six hundred-micrometer cores were taken from salivary gland tumor samples archived at the Stanford University Medical Center, Department of Pathology, between 1995 and 2009.
Clinical Features of Patients
The TMA consisted of tumor tissues from 52 patients with primary adenoid cystic carcinoma arising from either major or minor salivary glands located at head and neck sites. All patients were treated at Stanford for their cancer between 1973 and 2006, and this retrospective study was approved by the Stanford Institiutional Review Board. Of these, 15 cases were excluded because of negative oligo-dT staining indicating poor tissue quality in 9 cases and uninterpretable FISH reading in 6 cases. Table 1 shows patient distributions for both analyzable and nonanalyzable samples. As shown, most analyzable patients were treated with surgery followed by radiation therapy (73%). A small percentage of the analyzable patients were treated with surgery alone for small tumors (11%) and the remaining patients were treated with either neutron beam radiotherapy or a combination of chemoradiotherapy with a photon beam for unresectable tumors. The distribution of the analyzable and nonanalyzable samples were similar, except for a statistically higher percentage of adenoid cystic carcinoma with a solid component in the nonanalyzable group and a nonstatistically higher percentage of nodal involvement in the analyzable group.
FISH Probe Construction FISH Method and Interpretation
The FISH come-together and break-apart assay was carried out using 3 bacterial artificial chromosomes (BAC) probes: 2 probes flanking the MYB gene (RP11-104D9-centromeric, RP11-1105M6-telomeric) and 1 probe located at the 3 0 end of the NFIB gene (RP11-413D24-telomeric) from the Human BAC Library RPCI-11 (BACPAC Resources Centre, Children's Hospital Oakland Research Institute, Oakland, CA). The FISH assay was carried out as described earlier elsewhere. 9 In brief, 6-m-thick sections of the TMA slides were pretreated with citric acid buffer (pH 6.0). Metaphases and metaphase slides were produced using standard methods. BACs were directly labeled with either Cy3 or Cy5 (GE Healthcare Biosciences, NJ). The chromosomal locations of all BACs were validated using normal metaphases (results not shown). Probe labeling and FISH were carried out using Vysis reagents according to the manufacturer's protocols (Vysis, IL). The slides were counterstained with 4,6-diamidino 2-phenylindole for microscopy. Signals were interpreted manually, and images were captured by using the Ariol software (Applied Imaging, CA). A cut-off of Z30 breaks of the 2 MYB probes per 100 nuclei was selected for a positive score.
IHC Antibody, Staining, Titering Use of Oligo-dT, and Interpretation
The primary antibodies used were Myb (clone 5E11, 1:200, citrate retrieval, Vector VectaStain Elite ABC kit), p63 (clone 4A4, 1:200, DAKO, Carpinteria, CA), and Kit (rabbit polyclonal, 1:50; DAKO, Carpinteria, CA). The Myb staining was titered on a TMA with 150 cases of neoplastic and non-neoplastic tissues. A titer that showed strong staining in the 2 adenoid cystic carcinoma cores, weak staining in the normal thymus as a positive control, and no nonspecific staining in other tissues was chosen.
We first assessed the quality of tissue preservation by performing RNA in situ hybridization for oligo-dT. The oligo-dT probe hybridizes to the polyA tail of messenger RNA and should strongly stain all well-preserved cells. A number of steps in the processing of clinical specimens can lead to degradation of macromolecules with RNA being among the most sensitive ones. Thus, RNA preservation (and oligo-dT hybridization) is a good indicator of tissue quality. Eleven adenoid cystic carcinomas and 3 other salivary gland tumors had poor oligo-dT staining and were excluded from further study. Myb and Kit immunohistochemistry was independently evaluated by 2 pathologists, and interpretation discrepancies were discussed to achieve consensus. For Myb, only nuclear staining was considered positive. Lesional tissues with strong staining in >50% of the neoplastic cells were scored as strongly positive. Weak or strong staining in <50% of the cells was scored as weakly positive. Less than 5% staining was scored as negative. Kit staining was scored as positive if >10% of the cells showed membrane or cytoplasmic reactivity.
Statistical Analysis
Statistical analysis was carried out using the Statview statistical software (Computing Resource Center, San Monica, CA). The Fisher exact test and the student t test were used to compare the patient tumor and treatment characteristics between analyzable and nonanalyzable patient groups. The Kaplan-Meier method was used to calculate time to local progression. Log-rank statistics were used to compare survival curves among different FISH groups. Multivariate analysis was not carried out due to the small sample size.
RESULTS
To determine clinical use of MYB translocation and the resulting Myb fusion protein expression, we studied adenoid cystic carcinoma and other salivary gland tumors in the adenoid cystic carcinoma diagnostic differential by both FISH and immunohistchemistry on TMAs. Of 52 patients with adenoid cystic carcinoma with available tissues, 9 patients had negative oligo-dT staining, indicating poor tissue quality, leaving 43 patients for further analysis. Of these, the FISH assay was interpretable in 37 adenoid cystic carcinomas: 18 (49%) cases had a FISH pattern of a translocation involving MYB and NFIB (Fig.  1A) ; 6 (16%) cases had an abnormal FISH pattern suggestive of a translocation of MYB but not necessarily involving NFIB (Figs. 1B-D) ; and 13 (35%) cases showed no evidence of MYB translocation based on the probes used. Three atypical patterns were noted (Figs. 1B-D): MYB 3 0 , MYB 5 0 , and NFIB all come together, an extra 5 0 MYB without association with NFIB, and MYB split without association with NFIB. There was no evidence of MYB and NFIB translocation in the 112 other, nonadenoid cystic carcinoma, and salivary gland tumors. In 1 case (donor ID 20387), a patient with a history of treated adenoid cystic carcinoma developed a presumed recurrent tumor at the original site, which had a histology that was more characteristic of a cellular mixed tumor than adenoid cystic carcinoma. Immunohistochemistry at the time of diagnosis could not provide support for adenoid cystic carcinoma. The tricolor FISH assay showed a MYB translocation in this case supporting the diagnosis of recurrent adenoid cystic carcinoma. Another case of epithelial myoepithelial carcinoma (donor ID 18351) also showed an abnormal FISH pattern.
The MYB translocation with NFIB results in a fusion protein that contains the amino terminal approximately 90% of the Myb protein. We therefore used a monoclonal mouse antibody directed at the N-terminus of Myb to stain a TMA containing the adenoid cystic carcinoma cases, 112 other salivary gland tumors, and 409 nonsalivary gland tumors.
Strong Myb expression, as measured by immunohistochemistry, was present in 24 of 37 (65%) wellpreserved adenoid cystic carcinoma cases (see oligo-dT in Materials and Methods). The Myb expression was predominantly present in the nucleus. A comparison with the p63 and Kit staining patterns indicated that Myb expression was confined to neoplastic cells with a basal phenotype ( Figs. 2A-C) . The protein levels decrease as the cells mature to luminal cells despite the continued presence of the MYB-NFIB translocation in these cells (Fig. 2D) . Table 2 shows the distribution of Myb and Kit staining for adenoid cystic carcinoma and other salivary gland tumors. Myb was strongly expressed in 14 of 18 (78%) adenoid cystic carcinoma cases with the balanced pattern of MYB-NFIB translocation (Table 1) . Myb was similarly expressed in 4 of 6 (67%) adenoid cystic carcinoma cases with an abnormal FISH pattern involving MYB. Six of 13 (46%) adenoid cystic carcinoma cases with a normal FISH pattern were positive for Myb. Myb was expressed focally and at very low levels in rare nonadenoid cystic carcinoma salivary gland tumors (Table 2 ; Fig. 2E ). Diffuse and strong staining was highly specific for adenoid cystic carcinoma among salivary gland tumors. In contrast, Kit expression was observed in a variety of different salivary gland tumors included in this cohort (Table 2) . Table 3 shows Myb expression in nonsalivary gland carcinomas. As shown, Myb is expressed in a number of other solid tumors. This expression was generally low and focal, but a subset of breast carcinomas (5 of 17, 29%), seminomas (7 of 21, 33%) (Fig. 2F) , colorectal carcinomas (3 of 11, 27%), and thymomas (3 of 3) showed strong staining.
Myb expression and MYB translocation status was correlated with clinicopathologic features of these 37 wellmeasured cases, which had a median clinical follow-up of 74.7 months (range, 21.0 to 246.5 mo) for all patients and 77.1 months (range, 23.2 to 217.5 mo) for living patients. Fourteen of 22 (64%) of living patients had follow-up >5 years. In addition, of the 22 patients who were alive at the last follow-up, 10 (45%) already had relapsed and 4 of 12 (33%) nonrelapsing patients were followed for >10 years. Numerically, the local relapse rate was highest for adenoid cystic carcinoma cases with a balanced MYB-NFIB translocation (Fig. 3) . The cases with an abnormal MYB FISH pattern have an intermediate rate of local relapse. However, these differences are not statistically significant. Table 4 shows the correlation between MYB translocation (including those with abnormal MYB FISH pattern) or Myb expression with other clinicopathologic parameters. There was a trend toward more perineural invasion (PNI), which was noted for adenoid cystic carcinoma with balanced MYB FISH translocation compared with those without any translocation. Fifteen of 18 (83%) of adenoid cystic carcinomas with balanced translocation had PNI compared with 7 of 13 (54%) patients without any translocation ( w 2 ; P = 0.07, Fisher exact test, 0.11). When the patients with abnormal MYB FISH pattern were also included; the trend was still there but the difference became less statistically significant (Table 4) . Interestingly, 2 patients, who presented with metastasis at diagnosis, did not have MYB translocation but did have strong Myb protein expression. There were no other statistically significant correlations between either MYB translocation or Myb expression with any other patient or tumor characteristics in this small patient cohort.
DISCUSSION
A number of salivary gland neoplasms have been associated with recurrent chromosomal abnormalities and resulting gene fusions. This includes pleomorphic adenoma (PLAG1 or NFIB and -HMGA2), mucoepidermoid carcinoma (MAML2-TORC1), and Warthin tumor (MAML2-TORC1). 8 Recently, a recurrent t(6;9) translocation was found in adenoid cystic carcinoma. 6 Later, it was determined that the translocation leads to the fusion of MYB and NFIB. This fusion leads to the deregulation of the expression of Myb, and is likely to be a critical step in oncogenesis for adenoid cystic carcinoma.
The finding of a recurrent gene fusion and subsequent aberrant expression involving MYB provides an opportunity for developing a clinically useful biomarker for diagnosis and prognosis. To address this question, we determined the MYB gene and Myb protein status for a series of analyzable 37 adenoid cystic carcinoma cases, 112 other salivary gland neoplasms, and 409 nonsalivary gland tumors. We found that the balanced translocation, involving MYB and NFIB, was present in approximately one half of adenoid cystic carcinoma cases (18 of 37, 49%). An additional subset of cases (6 of 37, 16%) had an abnormal MYB FISH pattern suggestive of an unusual translocation of MYB but not involving NFIB. It is possible that this might be in part due to a local duplication of MYB, as has been reported in human T-ALL cells. 4 As seen in other salivary gland tumor translocations, a significant subset of cases did not have apparent MYB involvement, suggesting an alternative mechanism for oncogenesis. Overall, 65% of adenoid cystic carcinoma cases have a FISH pattern suggestive of MYB translocation. This is consistent with earlier published chromosomal analyses, suggesting that only a subset of adenoid cystic carcinomas harbor recurrent chromosomal rearrangements.
Myb protein expression is seen in a similar fraction of adenoid cystic carcinomas (27 of 37, 65%). It is highly correlated with MYB FISH translocation (18 of 24, 75%) but also positive in a subset of cases without the MYB translocation (6 of 13, 46%). Among salivary gland tumors, strong diffuse Myb expression is restricted to adenoid cystic carcinomas. Focal, weak nuclear staining of Myb was seen in a small subset of salivary gland tumors and this could pose a diagnostic problem if used in the clinical setting on small samples (eg, fine needle aspirates). Nevertheless, Myb protein expression or MYB translocation, as shown by FISH, may be helpful for the diagnosis of salivary gland lesions that are difficult to diagnose. In a survey of 409 nonsalivary gland neoplasms, Myb protein expression was seen in a significant subset of breast cancers, colorectal carcinomas, thymomas, and germ cell tumors. This suggests that some caution should be exercised if Myb protein expression is to be used in the diagnosis of metastatic adenoid cystic carcinoma.
Outcome studies provide some evidence to suggest that there is clinical prognostic significance to the presence of the MYB translocation. In our study of 37 wellmeasured cases, there is a trend toward an increase in local relapse with cases that have a balanced MYB-NFIB translocation. There is also a suggestion that these cases are more likely to show PNI. These results are similar to the findings in low-grade mucoepidermoid carcinoma, which show a difference in the outcome between tumors that bear a translocation versus those that do not. Earlier studies have shown that the MECT1-MAML2 translocation is present in a subset of low-grade mucoepidermoid carcinomas (and Warthin tumors). Patients with low-grade mucoepidermoid carcinoma and the MECT1-MAML2 translocation have a statistically significantly lower risk of local recurrence, distance recurrence, and death. 1 Extensive work has been done on the biology of MYB in relation to cell development and differentiation. 7 However, comparatively little is known about MYB in tumorigenesis in humans. We found that Myb expression is restricted to the basal cell phenotype within adenoid cystic carcinoma. Myb expression is lost in the luminal cells. It is surprising that both the basal cells and luminal cells have the MYB-NFIB translocation. These results suggest that there are intact regulatory mechanisms in these neoplastic cells that can shut off the expression of the MYB-NFIB fusion transcript and/or regulate levels of the fusion protein. It is possible that the oncogenically active cells (including the tumor-initiating cells) are present mainly in the basal cell population. Kit expression is seen in the luminal cells. On account of high Kit expression in these tumors, investigators have tried to target Kit-expressing adenoid cystic carcinomas with imatinib (a Kit inhibitor) without success. 2 The finding that MYB is only expressed in basal cells and not in the cells that express Kit suggests that strategies to target Kit may have been directed at the wrong cell phenotype or that Myb might lie upstream of Kit and be a more important target in adenoid cystic carcinoma.
In summary, we have found that over 50% of adenoid cystic carcinoma tumors harbor MYB translocations and increase Myb expression, a feature that is unique compared with other nonadenoid cystic carcinomas, salivary gland cancers, and provides a useful diagnostic tool. There was a trend toward increased PNI and higher rate with local relapse in patients with balanced MYB-NFIB translocation. Drawbacks of this study included its small sample size, the large percentage of nonanalyzable patients due to poor tissue quality, heterogeneity of treatment approaches, and the long period over which the patient data and tissues were collected. However, the follow-up is quite mature for adenoid cystic carcinoma with over half of living patients having greater than 5-year follow-up. The results of this 
